ropeginterferon alfa- 2b

DRUG2 trials

Sponsors

University of Utah, M.D. Anderson Cancer Center

Conditions

Alfa-2bAzacitidineMDS/AMLMyelofibrosisRopeginterferon

Phase 1

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

Not yet recruitingNCT07521046

University of UtahMyelofibrosis

Start: 2026-08-01End: 2030-08-01Target: 15Updated: 2026-07-08

A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations

Not yet recruitingNCT07646821

M.D. Anderson Cancer CenterAlfa-2b, Azacitidine, MDS/AML +1

Start: 2026-11-27End: 2030-12-11Target: 30Updated: 2026-08-25